The PI3K/AKT/mTOR pathway involves receptor tyrosine kinases (RTKs) such as EGFR and a tumour suppressor protein, PTEN, which acts as an antagonist of PI3K, contributing to the downregulation of this pathway and inhibiting cell proliferation. This evidence concerns the gene EGFR and neoplasm.